Semaglutide-Linked Suicidal Ideation ID'd in Disproportionality Analysis
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 21, 2024 -- Semaglutide-associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open.
Georgios Schoretsanitis, M.D., Ph.D., from Northwell Health in Glen Oaks, New York, and colleagues examined potential signals for suicidal and self-injurious adverse drug reactions (ADRs) associated with the glucagon-like peptide 1 receptor agonists semaglutide and liraglutide in a disproportionality analysis. Participants were patients experiencing an ADR, which was suspected as attributable to semaglutide or liraglutide.
Overall, 107 and 162 cases of suicidal and/or self-injurious ADRs were reported between November 2000 and August 2023 for semaglutide and liraglutide, respectively. The researchers detected significant disproportionality for semaglutide-associated suicidal ideation (reporting odds ratio, 1.45), which remained significant for those coreporting antidepressant and benzodiazepine use (reporting odds ratios, 4.45 and 4.07, respectively) and compared with dapagliflozin, metformin, and orlistat (reporting odds ratios, 5.56, 3.86, and 4.24, respectively).
"We reported a disproportionality signal of suicidal ideation with semaglutide, but not for liraglutide, particularly among patients with coreported antidepressant use, a proxy for affective disorders (a notable exclusion criteria of premarketing clinical trials)," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Mortality Increased With Hospital-Based Care for Hallucinogen Use
MONDAY, March 3, 2025 -- Hospital-based care for hallucinogen use is associated with increased mortality, according to a study published online March 3 in CMAJ, the journal of the...
GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk
MONDAY, March 3, 2025 -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4)...
Behavioral, Developmental Disorders in Children More Common in Recent Years
WEDNESDAY, Feb. 26, 2025 -- The prevalence of children's behavioral and developmental disorders increased nationally from 2019 to 2022, with some conditions linked to caregivers'...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.